Clinical Trials Browser

Withdrawn × Squamous Cell Carcinoma of Head and Neck × olaparib × Clear all

NCT02686008 2020-01-13

Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC

Phase 1 Withdrawn

Squamous Cell Carcinoma of Head and Neck